Abiomed has a Class I TAVR-related recall, Abbott bets on pipeline to build momentum

Abbott has now seen two quarters in a row of double-digit organic sales growth in its underlying business. Now the company is betting on its productive, innovative pipeline to build momentum. Fast Five hosts Sean Whooley and Danielle Kirsh go over the full performance of the company and how each of its segments performed. Johnson & Johnson MedTech posted revenues of $7.9 billion, marking a 12.9% improvement year-over-year. Learn what the growth drivers were for the MedTech segment and what analyst's think about the second-quarter results.  The initiation of Magnus Medical's neurostim trial marks a significant milestone in the field of mental health treatment, offering hope for patients with treatment-resistant depression. Whooley and Kirsh discuss the company's technology and the potential impact it could have on the treatment of treatment-resistant depression.  MediView XR announced this week that it received FDA 510(k) clearance for its XR90 augmented reality-based visualization and navigation platform. Find out the purpose of the AR platform and how it works to address the limitations of traditional medical imaging technologies. Johnson & Johnson’s Abiomed unit issued another recall for some of its Impella heart pumps. The recall is for TAVR-related devices. Whooley explains the reason for the recall, the risks involved and provides comments from Abiomed on the situation.  Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.